NKGen Biotech, Inc. has secured $2 million in funding from a Japanese strategic investor, aiding in the development of their NK cell therapy, troculeucel, for the Japanese market. The investment comes at a critical time, helping the company meet reporting requirements and clinical trial goals. Due to previous challenges, the company’s shares will temporarily trade on the OTC Expert Market, with plans to uplist to OTCQB once SEC filings are current. NKGen aims to return to Nasdaq or NYSE American, pending compliance with listing requirements. The company is committed to bringing troculeucel to market for neurodegenerative disorders and cancers.

Read more at GlobeNewswire: NKGen Biotech Announces New Funding to Regain Compliance